Overview

Safety, Tolerability and Pharmacokinetics of GSK1034702 in Healthy Subjects

Status:
Completed
Trial end date:
2008-12-15
Target enrollment:
Participant gender:
Summary
This is a First Time in Human Study to assess the safety, tolerability and pharmacokinetics of single doses of GSK1034702 in healthy subjects. It will be a single-blind, randomized, placebo-controlled, single oral dose, dose-rising, cross-over study in healthy male and female (of non-child bearing potential) subjects. Subjects will be randomized into cohorts of 10 subjects and cohorts will be recruited until the pre-defined safety or PK stopping limits are reached. Each subject will receive placebo and up to 4 doses of GSK1034702 in a randomized sequence on 5 separate study occasions.
Phase:
Phase 1
Details
Lead Sponsor:
GlaxoSmithKline